SHARE

Dr. Martens stays on track for FY26 profit growth

Dr. Martens said Q3 revenue fell 2.7% to £253m as it reduced discounting to improve full-price mix, while wholesale grew 9.5%. The group said it remains on track for significant year-on-year profit growth, led by strength in the Americas.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.